How can you understand billions of datapoints to fight complex diseases and develop personalised medicine, nutrition and health and wellness solutions?

PrecisionLife’s technology interprets complex biological data and other influences to develop our understanding of how foods, medicines and healthcare can be combined to improve peoples’ lives.

Using its powerful analytics platform, PrecisionLife conducts large-scale population studies, furthering our understanding of the biology that drives complex diseases – like dementia, COPD, cardiovascular or metabolic disease – and using this to build personalized models of risk factors and predicted therapy responses for individual patients.

For example, when applied to COVID-19 patient data, PrecisionLife identified 59 existing drugs that could be used to increase the survival rate of patients who develop sepsis while suffering from the disease and 68 genes which could help identify high-risk patients at greatest risk of developing the most severe forms of COVID-19. Similar studies are helping in the fight against asthma, Alzheimer's, ALS and breast cancer.

As well as providing the ability to drive valuable insights from human biological data, PrecisionLife’s technology also has wide applications in the food and agricultural sector.

Find out more.

Support from Grosvenor Food & AgTech has enabled PrecisionLife to develop groundbreaking analytical approaches to some of the most complex human health challenges. At the same time these developments are creating new commercial opportunities in animal and crop breeding and health.

Steve Gardner
Co-founder and Chief Executive Officer, PrecisionLife

For more information on Grosvenor Food & AgTech's investment in PrecisionLife please contact:

profile of Dr. Peter Kristensen

Dr. Peter Kristensen

Managing Partner, Grosvenor Food & AgTech

+44 207 3122 789

Related content

Group 2